PDF version



1. Submission
Abstracts must conform exactly to the following policies and procedures. Failure to submit you’re abstract as outlined below will mean that your abstract will not be considered for selection.

2. Selection
All abstracts are peer-reviewed and ranked on the basis of scientific merit. The GESA AGW 2017 Scientific Program Committee (SPC) will use these rankings to develop the final program.

3. Anonymity
You will be asked to supply 2 versions of your paper; one in an anonymous format for review and the other clearly identifying the author(s) as per point 11 below, for publishing.

To allow your abstract to be considered objectively and on an equal footing by the review panel it is important that your anonymous version does not contain the name(s) of the author(s) or of any other people. It also should not contain the name of any institution involved in any way in the research which is the subject of the abstract.

4. Type of Presentation
Abstracts are allocated as oral Free Papers or as Poster Sessions, based on the breadth or focus of interest and other considerations.

5. Poster Presentation
Following assessment the poster program will be developed in selected categories. The top ranked posters will form the Poster of Merit sessions. The timing of the program will be advertised in the conference program book.

6. Publication Charge
A charge of AUD$70.00 (plus.10% GST) – $77.00 per submitted abstract will apply to cover the cost of publication on the Journal of Gastroenterology and Hepatology’s website Payments must be made by credit card, in Australian Dollars at the time of submission on the GESA AGW 2017 website.

7. Publication
All abstracts accepted will be published on the Journal of Gastroenterology and Hepatology website.

8. Originality & Ethics

  • At the time of submitting your abstract the data must not have been presented at any other Australian meeting nor published as a proffered paper in Australia.

  • If your abstract has been presented at an International meeting but has not been published as a peer reviewed paper it will be accepted to be presented in Australia.

  • If the research presented was supported by a commercial organisation a completed “Conflict of Interest” form must be submitted to the Congress office via the GESA AGW 2017 website.

  • If the research involved human subjects, it must have been approved by your Institutional Review Board or Human Ethics Committee and conform to International Standards of Ethical Practice. Animal research must have been approved by an appropriate Review Board and conform to the highest standards of human care.

9. Disclosure of Conflict of Interest
All abstract presenters are expected to disclose to the audience any significant financial interest or other relationship with the manufacturer of any commercial product(s) and/or provider(s) of commercial services discussed in the presentation; and any commercial supporters of the presentation.

The intent of the disclosure is not to prevent a speaker with a significant financial or other relationship with a commercial company from making a presentation, but rather to provide the audience with information with which they can form their own opinions as to whether a presentation is biased or not. It remains for the audience to determine whether the speaker’s interests or relationships have influenced the presentation.

Significant financial interest or other relationship may include such things as:

  • Support of individual or department research;
  • Any support or financial incentives, current or past which relate to the subject matter of the current presentation;
  • Any stock ownership or options, employment loan or financial relationship with a company whose product or service is directly connected to the topic of the presentation;
  • Being a consultant for a company whose product or service would be directly affected by the subject matter of the current presentation;
  • No commercial literature or audiovisual material may be used; and/or
  • Trade or commercial names should be avoided unless necessary for clarity.

All presentations must be free of any commercial bias.

10. Attendance

An author of the abstracts selected for participation in the program, must attend the meeting and pay the relevant registration fee.

11. Instructions for Preparation
Abstract Categories

These categories are used to classify abstracts for review etc. You will be asked to select one of these categories when uploading your abstract onto the GESA AGW 2017 website.

  • Basic Science Liver
  • Basic Science Luminal
  • Endoscopy Lower
  • Endoscopy Upper
  • Gastrointestinal Cancer
  • Hepatitis – Viral
  • Hepatology Clinical
  • Inflammatory Bowel Disease  Basic
  • Inflammatory Bowel Disease  Clinical
  • Luminal Clinical
  • Motility/Neurogastroenterology
  • Nursing
  • Nutrition
  • Paediatrics
  • 2017 GESA Research Workshop
  • Surgery


The abstract title should be in initial capital/lower case, not all capitals.


Authors’ names should be supplied in the surname-last format and should be in initial capital/lower case, not all capitals.  Institution affiliations should be indicated with superscript numbers following the author name.

Presenting Author
Please clearly indicate who the presenting author is, should your abstract be selected for participation in the program.


All affiliations should contain institution, city and country.

Abstract Text:
Sub-headings e.g. Introduction, Method. Results etc. may be included if required.


(Optional) References can be included in the abstract text or as a list following the abstract. The style of the references should follow the style of the JGH Journal e.g. numbered or author/date style. Any references included in a reference list must be cited within the abstract text.

Tables & Graphs
Tables and figures can be included and must be cited in the abstract text.  The abstract themselves must be in the text, not table format.

Do not submit separate graphs or tables.


Abbreviations should conform to the Style Manual for Biological Journals. Avoid abbreviations in the abstract title. Place non-standard abbreviations in parentheses after the full word the first time it appears. Use no more than three (3) non-standard abbreviations.

Drug Names
Drug products mentioned in the abstract should be identified by their non-proprietary (i.e. generic) name only. Do not capitalise non-proprietary names.

Anonymous Version – Should be identified to reflect the abstract title.
Authored Version – To enable your abstract to be identified your surname must appear in the name of the abstract for example “smithagw2016abstract”

Do’s & Don’ts

  • Ensure abstract does not exceed one (1) A4 sheet of paper.
  • Keep italics and Greek symbols to a bare minimum.
  • Ensure that all track changes have been removed from the abstract.
  • Proof read your abstract (abstracts are printed as submitted).


  • Use any font smaller than Times Roman 11 point (10 point on figures and footnotes) when printed;
  • Indent at the beginning of paragraphs;

12. Submission
You must submit your abstract online.  Abstracts that do not comply with the above criteria will not be accepted.

13. Deadline
Abstracts and payment must be received no later than 17:00 Australian Eastern Standard Time on Monday, 15 May 2017. No abstracts will be accepted after this date.

You will be advised by email late June 2017 whether your abstract has been accepted and, if so, what format of presentation it has been chosen for.

14. Checklist

Before submitting your abstract, check that you have:

  • Removed all track changes
  • Adhered to all requirements (including ethics)
  • Carefully proof read your abstract


Click here to make a submission.